Infection
Conditions
Brief summary
The goal of tish clinical research study is to identify that loading of vancomycin can facilitate rapid attainment of target trough serum vancomycin concentration.
Detailed description
The Study drug * Vancomycin : a glycopeptide antibiotic, is the first line agent in the treatment of methicillin resistant staphylococcus aureus Study design : Randomized controlled trials Study Drug Administration * If your doctor believes you are eligible, and you agree to take part in this study, you will be randomized to two treatment groups.
Interventions
DRUGVancomycin HCL
Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours. Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day.
Sponsors
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Admission to Samsung Medical Center MICU and general wards for infectious diseases and hematology division * Patients with SIRS (systemic inflammatory response syndrome) * Intravenous vancomycin therapy deemed necessary
Exclusion criteria
* Age less than 20 years * Age more than 75 years * Current renal insufficiency defined as estimated Glomerular filtration rate \< 50mg/min/1.73 m2 by MDRD equation * History of adverse events to vancomycin 5. Pregnant woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time duration for concentration of vancomycin to reach target trough of 15-20 mg/L | Peak level drawn 1 hour after the completion of loading dose. Sequential trough level drawn 30 min before each standard dose for the next 4 doses. |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event rate in each arm, including nephrotoxicity and rash. | 7 days post-treatment |
Countries
South Korea
Outcome results
None listed